Artivion Q2 FY26 GAAP net loss widens to $13.5 million; revenue rises 11% to $125.8 million - AORT News | RalliesArtivion Q2 FY26 GAAP net loss widens to $13.5 million; revenue rises 11% to $125.8 million
A
AORT• Q2 results and outlook
- Artivion Q2 2026 revenue rose 11% to USD 125.8 million; GAAP net results swung to a loss of USD 13.5 million.
- Adjusted EBITDA increased 7% to USD 26.4 million; non-GAAP net income fell to USD 6.3 million.
- U.S. FDA granted PMA approval for the AMDS Hybrid Prosthesis; acquisition of Endospan closed, adding the NEXUS Aortic Arch Stent Graft System.
- Full-year 2026 outlook reiterated: revenue USD 480 million to USD 496 million; adjusted EBITDA USD 92 million to USD 99 million.
CTVA
•
